HRP20141158T1 - Postupak za dijagnosticiranje raka koji izražava skraä†enu varijantu her2-receptora - Google Patents
Postupak za dijagnosticiranje raka koji izražava skraä†enu varijantu her2-receptora Download PDFInfo
- Publication number
- HRP20141158T1 HRP20141158T1 HRP20141158AT HRP20141158T HRP20141158T1 HR P20141158 T1 HRP20141158 T1 HR P20141158T1 HR P20141158A T HRP20141158A T HR P20141158AT HR P20141158 T HRP20141158 T HR P20141158T HR P20141158 T1 HRP20141158 T1 HR P20141158T1
- Authority
- HR
- Croatia
- Prior art keywords
- cancer
- antibody
- her2
- receptor
- seq
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims 9
- 238000000034 method Methods 0.000 title claims 9
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 title 1
- 239000012634 fragment Substances 0.000 claims 22
- 201000011510 cancer Diseases 0.000 claims 8
- 238000001514 detection method Methods 0.000 claims 5
- 238000004393 prognosis Methods 0.000 claims 5
- 210000004408 hybridoma Anatomy 0.000 claims 4
- 230000002265 prevention Effects 0.000 claims 3
- 238000003364 immunohistochemistry Methods 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000005012 migration Effects 0.000 claims 2
- 238000013508 migration Methods 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 239000000523 sample Substances 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010008642 Cholesteatoma Diseases 0.000 claims 1
- 208000005243 Chondrosarcoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 206010014967 Ependymoma Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 208000006168 Ewing Sarcoma Diseases 0.000 claims 1
- 201000001342 Fallopian tube cancer Diseases 0.000 claims 1
- 208000013452 Fallopian tube neoplasm Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010023825 Laryngeal cancer Diseases 0.000 claims 1
- 206010061523 Lip and/or oral cavity cancer Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 208000000172 Medulloblastoma Diseases 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 208000003445 Mouth Neoplasms Diseases 0.000 claims 1
- 208000010505 Nose Neoplasms Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 claims 1
- 206010061934 Salivary gland cancer Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- 206010043515 Throat cancer Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 208000004354 Vulvar Neoplasms Diseases 0.000 claims 1
- 208000008383 Wilms tumor Diseases 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 239000012752 auxiliary agent Substances 0.000 claims 1
- 238000004113 cell culture Methods 0.000 claims 1
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 238000000684 flow cytometry Methods 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 239000001963 growth medium Substances 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 230000003053 immunization Effects 0.000 claims 1
- 238000002649 immunization Methods 0.000 claims 1
- 238000010166 immunofluorescence Methods 0.000 claims 1
- 230000002163 immunogen Effects 0.000 claims 1
- 230000016784 immunoglobulin production Effects 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 206010023841 laryngeal neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 239000002609 medium Substances 0.000 claims 1
- 201000008026 nephroblastoma Diseases 0.000 claims 1
- 208000007538 neurilemmoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000013610 patient sample Substances 0.000 claims 1
- 201000002628 peritoneum cancer Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 206010042863 synovial sarcoma Diseases 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 208000029387 trophoblastic neoplasm Diseases 0.000 claims 1
- 230000004614 tumor growth Effects 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
- 201000005102 vulva cancer Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3015—Breast
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Food Science & Technology (AREA)
- Hospice & Palliative Care (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Wood Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Peptides Or Proteins (AREA)
Claims (25)
1. Protutijelo ili njegov fragment, naznačen/o time, da ono prepoznaje epitop od HER2-receptora u skraćenom obliku, koji je određen sa SEQ ID NO:1, gdje je navedeni epitop određen sa sekvencom uključenom u SEQ ID NO:2, pri čemu je protutijelo ili njegov fragment sposobno/sposoban razlikovati protein sa SEQ ID NO:1 od HER2-receptora.
2. Protutijelo ili njegov fragment prema zahtjevu 1, naznačen/o time, da navedeni epitop je onaj koji je uključen u SEQ ID NO:3.
3. Protutijelo ili njegov fragment prema jednom ili više od prethodnih zahtjeva, naznačen/o time, da protutijelo ili njegov fragment je sposobno/sposoban razlikovati protein sa SEQ ID NO:1 od skraćenog oblika 648-CTF/p95 od HER2-receptora.
4. Protutijelo ili njegov fragment prema zahtjevu 2 ili 3, naznačen/o time, da se razlika može vizualizirati pomoću jedne ili više od sljedećih metoda: imunofluorescencija, citometrijski protok, imunohistokemija u staničnim kulturama i imunohistokemija u uzorcima od pacijenata.
5. Protutijelo ili njegov fragment prema jednom ili više od prethodnih zahtjeva, naznačen/o time, da je to poliklonalno protutijelo.
6. Protutijelo ili njegov fragment prema jednom ili više od zahtjeva 1 do 4, naznačen/o time, da je to monoklonalno protutijelo ili njegov fragment.
7. Protutijelo ili njegov fragment prema zahtjevu 6, naznačen/o time, da se proizvodi pomoću stanične linije hibridoma, deponirane kod “Deutschland Sammlung von Mikroorganismen und Zellen - DSMZ” s pristupnim brojem DSM ACC2904, ili pomoću stanične linije hibridoma, deponirane kod “Deutschland Sammlung von Mikroorganismen und Zellen - DSMZ” s pristupnim brojem DSM ACC2980.
8. Protutijelo ili njegov fragment prema jednom ili više od prethodnih zahtjeva, naznačen/o time, da je taj fragment odabran iz skupine koju čine F(ab), F(ab’) i Fv.
9. Hibridom, naznačen time, da on proizvodi monoklonalno protutijelo prema zahtjevu 6 ili 7.
10. Peptid koji se sastoji od SEQ ID NO:3 ili SEQ ID NO:4, naznačen time, da je opcijski konjugiran s imunogenom i upotrebljava se u postupku proizvodnje protutijela prema jednom ili više zahtjeva 1 ili 2, dok taj postupak uključuje imunizaciju sa spomenutim peptidom.
11. Postupak dobivanja monoklonalnog protutijela, naznačen time, da se stanična linija hibridoma uzgaja u prikladnom mediju za kultiviranje i zatim se monoklonalno protutijelo obnavlja iz toga medija.
12. Postupak dijagnosticiranja raka, naznačen time, da obuhvaća otkrivanje prisutnosti HER2-receptora skraćenog oblika, koji sadrži aminokiselinsku sekvencu SEQ ID NO:1, u uzorku od pacijenta, pri čemu se to pronalaženje izvodi pomoću načina neovisno izabranog iz skupine koju čine:
(i) otkrivanje preko diferencijalne migracije HER2-receptora skraćenog oblika, koji se sastoji od SEQ ID NO:1, u odnosu prema cjelovitom obliku navedenog HER2-receptora; i
(ii) otkrivanje pomoću vezivanja s jednim ili više protutijela koja su definirana u jednom ili više od zahtjeva 1 do 11.
13. Postupak prema zahtjevu 12, naznačen time, da je to prognostički postupak koji omogućava prognoziranje povećanja rasta tumora i/ili metastaza.
14. Uporaba protutijela ili njegovog fragmenta prema bilo kojem od zahtjeva 1 do 8, naznačena time, da je za dijagnosticiranje i određivanje prognoze u izoliranim uzorcima raka u kojima se izražava HER2-receptor.
15. Sredstvo za dijagnosticiranje i određivanje prognoze u izoliranim uzorcima raka tipa koji izražava HER2-receptor ili njegove skraćene varijante, naznačeno time, da obuhvaća najmanje jedno protutijelo ili njegov fragment prema bilo kojem od zahtjeva 1 do 8.
16. Sredstvo za dijagnosticiranje prema zahtjevu 15, naznačeno time, da je protutijelo ili njegov fragment smješteno/smješten na čvrstom osloncu.
17. Garnitura za dijagnosticiranje i određivanje prognoze u izoliranim uzorcima raka tipa koji izražava HER2-receptor ili njegove skraćene varijante, naznačena time, da obuhvaća protutijelo ili njegov fragment prema bilo kojem od zahtjeva 1 do 8, za otkrivanje prisutnosti HER2-receptora skraćenog oblika, koji sadrži SEQ OD NO:1, u uzorku.
18. Garnitura za dijagnosticiranje i određivanje prognoze prema zahtjevu 17, naznačena time, da način otkrivanja obuhvaća najmanje jedno sredstvo prema zahtjevima 15 ili 16.
19. Garnitura za dijagnosticiranje i određivanje prognoze prema zahtjevu 17, naznačena time, da se način pronalaženja sastoji od otkrivanja pomoću diferencijalne migracije, HER2 receptora skraćenog oblika sa SEQ ID NO:1, u odnosu prema cjelovitom obliku spomenutog HER2-receptora.
20. Protutijelo ili njegov fragment prema jednom ili više od zahtjeva 1 do 9, naznačen/o time, da se upotrebljava za terapeutske svrhe.
21. Protutijelo ili njegov fragment prema zahtjevu 20, naznačen/o time, da se upotrebljava za liječenje ili prevenciju raka kod kojega se izražava barem HER2-receptor skraćenog oblika, koji sadrži SEQ ID NO:1.
22. Protutijelo ili njegov fragment prema zahtjevu 21, naznačen/o time, da se upotrebljava za liječenje ili prevenciju raka dojke kod sisavaca, uključujući i ljude.
23. Protutijelo ili njegov fragment prema zahtjevu 21, naznačen/o time, da se upotrebljava za liječenje ili prevenciju raka odabranog iz skupine koju čine: rak pluća, rak gušterače, rak debelog crijava, rak želuca, rak prostate, rak glave i vrata, rak kože, rak bubrega, rak testisa, rak štitnjače, rak mokraćnog mjehura, rak maternice, rak vulve, endometrijski rak, rak jajnika, rak jednjaka, rak usta, rak žlijezda slinovnica, rak grkljana, peritonealni rak, rak područja nosa i grla, rak Falopijeve tube, Wilmsovi tumori, kao što su limfomi, Ewingov sarkom, sinovijalni sarkom, meduloblastomi, trofoblastični tumori, gliomi, glioblastomi, kolangiokarcinomi, kolesteatomi, kondrosarkomi, ependimomi, neurilemomi, neoromi, rabdomiosarkomi.
24. Uporaba protutijela ili njegovog fragmenta prema jednom ili više od zahtjeva 1 do 8, naznačena time, da je za proizvodnju lijeka za liječenje raka u kojem se izražava barem skraćeni oblik HER2-receptora koji sadrži SEQ ID NO:1.
25. Farmaceutski sastav za liječenje raka u kojem se izražava barem skraćeni oblik HER2-receptora koji sadrži SEQ ID NO:1, naznačen time, da obuhvaća protutijelo ili njegov fragment prema bilo kojem od zahtjeva 1 do 8, i najmanje jedno farmaceutski prihvatljivo pomoćno sredstvo i/ili nosač.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES200801652A ES2342646B1 (es) | 2008-06-02 | 2008-06-02 | Metodo de diagnostico de canceres que expresan el receptor her-2 o sus variantes truncadas. |
| PCT/EP2009/056976 WO2010000565A1 (en) | 2008-06-02 | 2009-06-05 | Method for diagnosing cancers expressing the her2 receptor or its truncated variants |
| EP09772265.6A EP2293819B1 (en) | 2008-06-02 | 2009-06-05 | Method for diagnosing cancers expressing a truncated her2 receptor variant |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20141158T1 true HRP20141158T1 (hr) | 2015-02-13 |
Family
ID=40911029
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20141158AT HRP20141158T1 (hr) | 2008-06-02 | 2014-11-27 | Postupak za dijagnosticiranje raka koji izražava skraä†enu varijantu her2-receptora |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US8389227B2 (hr) |
| EP (1) | EP2293819B1 (hr) |
| JP (2) | JP5753079B2 (hr) |
| KR (2) | KR101785117B1 (hr) |
| CN (1) | CN102202692B (hr) |
| AU (2) | AU2009265921B2 (hr) |
| BR (1) | BRPI0914969A2 (hr) |
| CA (1) | CA2727365A1 (hr) |
| CY (1) | CY1115798T1 (hr) |
| DK (1) | DK2293819T3 (hr) |
| EA (1) | EA025218B1 (hr) |
| ES (2) | ES2342646B1 (hr) |
| HK (1) | HK1157658A1 (hr) |
| HR (1) | HRP20141158T1 (hr) |
| IL (1) | IL209769A (hr) |
| MX (1) | MX2010013419A (hr) |
| PL (1) | PL2293819T3 (hr) |
| PT (1) | PT2293819E (hr) |
| SI (1) | SI2293819T1 (hr) |
| WO (1) | WO2010000565A1 (hr) |
| ZA (1) | ZA201009010B (hr) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7638598B2 (en) * | 2001-04-06 | 2009-12-29 | The Trustees Of The University Of Pennsylvania | ErbB interface peptidomimetics and methods of use thereof |
| CA2711843C (en) | 2007-12-20 | 2018-11-13 | Laboratory Corporation Of America Holdings | Her-2 diagnostic methods |
| ES2342646B1 (es) * | 2008-06-02 | 2011-04-26 | Institut De Recerca Hospital Universitari Vall Hebron | Metodo de diagnostico de canceres que expresan el receptor her-2 o sus variantes truncadas. |
| ES2637411T3 (es) * | 2008-12-01 | 2017-10-13 | Laboratory Corporation Of America Holdings | Métodos y ensayos para medir p95 Y/O p95 en una muestra y anticuerpos específicos para p95 |
| EP2387711B1 (en) | 2009-01-15 | 2015-04-22 | Laboratory Corporation of America Holdings | Methods of determining patient response by measurement of her-3 |
| NZ616755A (en) * | 2009-05-14 | 2015-05-29 | Nestec Sa | Biomarkers for determining sensitivity of breast cancer cells to her2-targeted therapy |
| SI2330131T1 (sl) * | 2009-12-07 | 2015-02-27 | Fundacio Privada Institucio Catalana De Recerca I Estudis Avancants | Protitelesa proti HER2 skrajšani varianti CTF-611 |
| CN103102414B (zh) * | 2013-02-04 | 2014-08-27 | 无锡傲锐东源生物科技有限公司 | 抗her2蛋白单克隆抗体及其用途 |
| US20160067307A1 (en) | 2013-05-01 | 2016-03-10 | Five Prime Therapeutics, Inc. | Methods of treating cancer |
| ES2864124T3 (es) | 2014-03-11 | 2021-10-13 | Molecular Templates Inc | Proteínas que comprenden regiones de unión, regiones efectoras de la subunidad A de toxina Shiga y motivos señal de localización de retículo endoplasmático carboxi terminal |
| RS62143B1 (sr) | 2014-03-11 | 2021-08-31 | Molecular Templates Inc | Proteini koji uključuju podjedinice proksimalnih aminoterminalnih efektorskih regiona šiga toksina i vezni regioni imunoglobulinskog tipa koji ciljaju ćelije sposobni da specifično vezuju cd38 |
| MX2017015493A (es) | 2015-05-30 | 2018-02-09 | Molecular Templates Inc | Andamiajes de la subunidad a de la toxina shiga desinmunizados y moleculas con direccion a las celulas que los comprenden. |
| MX2018001208A (es) | 2015-07-26 | 2018-03-26 | Molecular Templates Inc | Moleculas con direccion a las celulas que comprenden efectores de la subunidad a de la toxina shiga y epitopos de celulas-t cd8+. |
| EP3455260B1 (en) | 2016-05-12 | 2022-07-06 | Agency for Science, Technology and Research | Anti-erbb-2 antibodies and uses thereof |
| CN109843926B (zh) | 2016-09-30 | 2023-01-20 | 豪夫迈·罗氏有限公司 | 针对cd3的双特异性抗体 |
| JP7082424B2 (ja) | 2017-01-25 | 2022-06-08 | モレキュラー テンプレーツ，インク． | 脱免疫化された志賀毒素ａサブユニットエフェクター及びｃｄ８＋ｔ細胞エピトープを含む細胞標的化分子 |
| MX2019009726A (es) | 2018-04-17 | 2020-02-05 | Molecular Templates Inc | Moleculas con direccion hacia her2 que comprenden andamiajes de la sub-unidad a de la toxina shiga desinmunizados. |
| CN110172448B (zh) * | 2019-05-30 | 2020-07-28 | 中南大学湘雅二医院 | 一种滑膜肉瘤细胞系hSS-005R及其子代细胞系 |
| EP4003407A1 (en) | 2019-07-23 | 2022-06-01 | Mnemo Therapeutics | Immune cells defective for suv39h1 |
| CN110865184B (zh) * | 2019-12-04 | 2023-04-07 | 广州医科大学附属第三医院（广州重症孕产妇救治中心、广州柔济医院） | Srsp蛋白和srsp抗原表位肽的应用及诊断和治疗肿瘤的产品 |
| EP3915576A1 (en) | 2020-05-28 | 2021-12-01 | Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron | Chimeric antigen receptors specific for p95her2 and uses thereof |
| WO2023126458A1 (en) | 2021-12-28 | 2023-07-06 | Mnemo Therapeutics | Immune cells with inactivated suv39h1 and modified tcr |
| EP4253418A1 (en) | 2022-03-29 | 2023-10-04 | Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron | Immune cells expressing chimeric antigen receptors and bispecific antibodies and uses thereof |
| EP4279085A1 (en) | 2022-05-20 | 2023-11-22 | Mnemo Therapeutics | Compositions and methods for treating a refractory or relapsed cancer or a chronic infectious disease |
| WO2024062138A1 (en) | 2022-09-23 | 2024-03-28 | Mnemo Therapeutics | Immune cells comprising a modified suv39h1 gene |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3040121B2 (ja) | 1988-01-12 | 2000-05-08 | ジェネンテク，インコーポレイテッド | 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法 |
| DE69535673D1 (de) | 1994-08-30 | 2008-02-07 | Univ Dundee | Mittel zur induktion von apoptosis und zur therapieanwendung |
| WO1998006863A1 (en) * | 1996-08-14 | 1998-02-19 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | A vector for polynucleotide vaccines |
| US7371376B1 (en) | 1996-10-18 | 2008-05-13 | Genentech, Inc. | Anti-ErbB2 antibodies |
| ZA9811162B (en) * | 1997-12-12 | 2000-06-07 | Genentech Inc | Treatment with anti-ERBB2 antibodies. |
| WO2000069460A1 (en) * | 1999-05-14 | 2000-11-23 | Genentech, Inc. | TREATMENT WITH ANTI-ErbB2 ANTIBODIES |
| DK1210115T3 (da) * | 1999-08-27 | 2009-11-30 | Genentech Inc | Doseringer til behandling med anti-ErB2-antistoffer |
| WO2005011607A2 (en) * | 2003-08-01 | 2005-02-10 | Smithkline Beecham Corporation | Treatment of cancers expressing p95 erbb2 |
| JP2006316040A (ja) * | 2005-05-13 | 2006-11-24 | Genentech Inc | Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法 |
| ES2342646B1 (es) * | 2008-06-02 | 2011-04-26 | Institut De Recerca Hospital Universitari Vall Hebron | Metodo de diagnostico de canceres que expresan el receptor her-2 o sus variantes truncadas. |
| ES2637411T3 (es) * | 2008-12-01 | 2017-10-13 | Laboratory Corporation Of America Holdings | Métodos y ensayos para medir p95 Y/O p95 en una muestra y anticuerpos específicos para p95 |
-
2008
- 2008-06-02 ES ES200801652A patent/ES2342646B1/es not_active Withdrawn - After Issue
-
2009
- 2009-06-05 SI SI200931079T patent/SI2293819T1/sl unknown
- 2009-06-05 US US12/479,035 patent/US8389227B2/en active Active
- 2009-06-05 EA EA201001874A patent/EA025218B1/ru not_active IP Right Cessation
- 2009-06-05 ES ES09772265.6T patent/ES2528132T3/es active Active
- 2009-06-05 CA CA2727365A patent/CA2727365A1/en not_active Abandoned
- 2009-06-05 PL PL09772265T patent/PL2293819T3/pl unknown
- 2009-06-05 DK DK09772265.6T patent/DK2293819T3/en active
- 2009-06-05 AU AU2009265921A patent/AU2009265921B2/en not_active Ceased
- 2009-06-05 PT PT97722656T patent/PT2293819E/pt unknown
- 2009-06-05 BR BRPI0914969A patent/BRPI0914969A2/pt not_active Application Discontinuation
- 2009-06-05 CN CN200980126660.1A patent/CN102202692B/zh active Active
- 2009-06-05 JP JP2011512150A patent/JP5753079B2/ja not_active Expired - Fee Related
- 2009-06-05 MX MX2010013419A patent/MX2010013419A/es active IP Right Grant
- 2009-06-05 EP EP09772265.6A patent/EP2293819B1/en active Active
- 2009-06-05 KR KR1020117000466A patent/KR101785117B1/ko active IP Right Grant
- 2009-06-05 KR KR1020167032972A patent/KR20160140974A/ko not_active Application Discontinuation
- 2009-06-05 WO PCT/EP2009/056976 patent/WO2010000565A1/en active Application Filing
-
2010
- 2010-12-05 IL IL209769A patent/IL209769A/en not_active IP Right Cessation
- 2010-12-14 ZA ZA2010/09010A patent/ZA201009010B/en unknown
-
2011
- 2011-11-10 HK HK11112126.9A patent/HK1157658A1/xx not_active IP Right Cessation
-
2014
- 2014-11-27 HR HRP20141158AT patent/HRP20141158T1/hr unknown
- 2014-11-28 CY CY20141100995T patent/CY1115798T1/el unknown
-
2015
- 2015-05-21 JP JP2015103316A patent/JP2015214546A/ja active Pending
- 2015-05-26 AU AU2015202854A patent/AU2015202854A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2015214546A (ja) | 2015-12-03 |
| US8389227B2 (en) | 2013-03-05 |
| CN102202692B (zh) | 2014-03-12 |
| KR20110031187A (ko) | 2011-03-24 |
| ES2528132T3 (es) | 2015-02-04 |
| EP2293819A1 (en) | 2011-03-16 |
| ZA201009010B (en) | 2012-03-28 |
| ES2342646B1 (es) | 2011-04-26 |
| JP2011525175A (ja) | 2011-09-15 |
| AU2009265921B2 (en) | 2015-04-02 |
| MX2010013419A (es) | 2011-08-15 |
| KR20160140974A (ko) | 2016-12-07 |
| EA201001874A1 (ru) | 2011-08-30 |
| EP2293819B1 (en) | 2014-09-03 |
| IL209769A (en) | 2016-04-21 |
| AU2009265921A1 (en) | 2010-01-07 |
| DK2293819T3 (en) | 2014-12-08 |
| IL209769A0 (en) | 2011-02-28 |
| WO2010000565A1 (en) | 2010-01-07 |
| US20090311262A1 (en) | 2009-12-17 |
| ES2342646A1 (es) | 2010-07-09 |
| KR101785117B1 (ko) | 2017-11-07 |
| CA2727365A1 (en) | 2010-01-07 |
| EA025218B1 (ru) | 2016-12-30 |
| AU2015202854A1 (en) | 2015-06-18 |
| JP5753079B2 (ja) | 2015-07-22 |
| PL2293819T3 (pl) | 2015-04-30 |
| PT2293819E (pt) | 2014-12-09 |
| CY1115798T1 (el) | 2017-01-25 |
| CN102202692A (zh) | 2011-09-28 |
| BRPI0914969A2 (pt) | 2015-10-20 |
| HK1157658A1 (en) | 2012-07-06 |
| SI2293819T1 (sl) | 2015-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20141158T1 (hr) | Postupak za dijagnosticiranje raka koji izražava skraä†enu varijantu her2-receptora | |
| Corbett et al. | NCL‐CB11, a new monoclonal antibody recognizing the internal domain of the c‐erbB‐2 oncogene protein effective for use on formalin‐fixed, paraffin‐embedded tissue | |
| Herlyn et al. | Monoclonal antibody detection of a circulating tumor-associated antigen. I. Presence of antigen in sera of patients with colorectal, gastric, and pancreatic carcinoma | |
| US9840551B2 (en) | Blood markers for diagnosing epithelium derived cancers and monoclonal antibodies thereof | |
| WO2008146911A9 (ja) | IL13Ra2に対する抗体およびこれを含む診断・治療薬 | |
| CN102245767B (zh) | 人cxcl1蛋白质的免疫学测定方法 | |
| JPH04503012A (ja) | Ｃ―ｅｒｂＢ―２外部ドメイン：ＧＰ７５ | |
| RU2009137784A (ru) | Человеческое опухолеспецифическое моноклональное антитело | |
| PT2330131E (pt) | Anticorpos contra a variante truncada de her-2 ctf-611 | |
| JP2016500659A (ja) | 抗ウロプラキンｉｉ抗体システムおよび方法 | |
| Hamilton et al. | Aberrant expression of the embryonic transcription factor brachyury in human tumors detected with a novel rabbit monoclonal antibody | |
| Matsuoka et al. | Recognition of ovarian cancer antigen CA125 by murine monoclonal antibody produced by immunization of lung cancer cells | |
| ES2233965T3 (es) | Anticuerpo monoclonal y antigeno relativo al adenocarcinoma pulmonar humano y metodo de inmunoensayo con el uso de los mismos. | |
| US20010046686A1 (en) | Sensitive detection of wild-type and mutant EGFR by specific ELISA assays in any biological sample | |
| US20210324059A1 (en) | Monoclonal antibodies against ambra-1 | |
| SA517390248B1 (ar) | Igr-1r جسم مضاد لـ واستخدامه لتشخيص السرطان | |
| CA2948743A1 (en) | Antibody binding to carbonic anhydrase and use thereof | |
| US20210396758A1 (en) | Monoclonal antibodies against loricrin | |
| CN101270161B (zh) | 抗人Reg4的单克隆抗体及其制备与应用以及杂交瘤细胞株 | |
| Rezaei et al. | Monoclonal antibody production against vimentin by whole cell immunization in a mouse model | |
| CN112557662B (zh) | 一种结直肠癌检测试剂盒 | |
| WO2023190820A1 (ja) | 抗ＣＫ２α抗体又はその断片 | |
| KR20100035404A (ko) | 신규 급성 골수성 백혈병 진단용 바이오마커 및 이의 항체를 이용한 치료제 | |
| JP2008249587A (ja) | カルモジュリンを標的とした腫瘍の判定方法 | |
| US20110171216A1 (en) | Monoclonal antibodies specific for pancreatic neoplasia cells |